{"id":209349,"date":"2024-07-19T09:30:00","date_gmt":"2024-07-19T13:30:00","guid":{"rendered":"https:\/\/ibkrcampus.com\/?p=209349"},"modified":"2024-07-29T16:33:16","modified_gmt":"2024-07-29T20:33:16","slug":"eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain","status":"publish","type":"post","link":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/","title":{"rendered":"Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain"},"content":{"rendered":"\n

Eli Lilly’s weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.<\/strong><\/p>\n\n\n\n

Eli Lilly and Company (NYSE: LLY<\/span>) announced today that its weight loss drug tirzepatide has received approval<\/a> from Chinese regulators.<\/p>\n\n\n\n

This development marks a significant expansion for the pharmaceutical giant in the world\u2019s second-largest economy, which is estimated to have the highest number of overweight or obese people globally. The approval intensifies competition with Novo Nordisk (NYSE: NVO<\/span>) in the Chinese market following the June 2024 approval<\/a> of Novo\u2019s weight loss drug Wegovy.<\/p>\n\n\n\n

Eli Lilly Gains Regulatory Approval in China for Weight Loss Drug<\/h2>\n\n\n\n

Tirzepatide, the active ingredient in Eli Lilly\u2019s diabetes drug Mounjaro and weight-loss drug Zepbound<\/a>, has gained regulatory approval in China.<\/p>\n\n\n\n

The company made the announcement via social media, though no immediate details were provided regarding the commencement of sales or supply amounts. This approval adds to tirzepatide\u2019s growing global presence, with previous approvals in the United States, European Union, Canada, Australia, and the United Kingdom for various indications, including type 2 diabetes treatment and weight loss management.<\/p>\n\n\n\n

LLY Stock Sees Slight Gains in Premarket Trading on the News<\/h2>\n\n\n\n

Following the news, Eli Lilly\u2019s stock (LLY) showed positive movement in pre-market trading<\/a>. As of 8:00 AM EDT, the stock was trading at $867.98, up 2.25% from its previous close of $848.90. The company\u2019s market capitalization stands at an impressive $764.35 billion, reflecting investor confidence in its growth prospects.<\/p>\n\n\n\n

Eli Lilly has demonstrated strong financial performance, significantly outperforming the S&P 500 index<\/a>. The stock has recorded a year-to-date return of 46.13%, a one-year return of 91.27%, and a remarkable five-year return of 752.79%.

Key financial metrics include a trailing P\/E ratio<\/a> of 125.02, an EPS of $6.79, and a profit margin of 17.08%. The company reported a trailing twelve-month revenue of $35.93 billion and a net income available to common shareholders of $6.14 billion.<\/p>\n\n\n\n

As Eli Lilly continues to expand its global footprint in the weight loss drug market, investors and industry observers will closely watch the company\u2019s performance in the competitive Chinese market. The approval of tirzepatide in China represents a significant milestone for Eli Lilly.<\/p>\n\n\n\n

—<\/p>\n\n\n\n

Originally Posted July 19, 2024 – Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain<\/a><\/p>\n\n\n\n

Disclaimer: The author does not hold or have a position in any securities discussed in the article.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly’s weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.<\/p>\n","protected":false},"author":501,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"footnotes":""},"categories":[6,8,9,22,26,3],"tags":[17516,11853,4109],"contributors-categories":[13710],"class_list":{"0":"post-209349","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-north-america","7":"category-region","8":"category-securities","9":"category-stocks","10":"category-text-articles","11":"category-traders-insight","12":"tag-eli-lilly","13":"tag-future-trends","14":"tag-stock-market","15":"contributors-categories-the-tokenist"},"pp_statuses_selecting_workflow":false,"pp_workflow_action":"current","pp_status_selection":"publish","acf":[],"yoast_head":"\nEli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain<\/title>\n<meta name=\"description\" content=\"Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interactivebrokers.com\/campus\/wp-json\/wp\/v2\/posts\/209349\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain | IBKR Campus US\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/\" \/>\n<meta property=\"og:site_name\" content=\"IBKR Campus US\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-19T13:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-29T20:33:16+00:00\" \/>\n<meta name=\"author\" content=\"Tim Fries\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tim Fries\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\n\t \"@context\": \"https:\\\/\\\/schema.org\",\n\t \"@graph\": [\n\t {\n\t \"@type\": \"NewsArticle\",\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\\\/#article\",\n\t \"isPartOf\": {\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\\\/\"\n\t },\n\t \"author\": {\n\t \"name\": \"Tim Fries\",\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/person\\\/8aec5ebeb263dcb77586039ad857f7ae\"\n\t },\n\t \"headline\": \"Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain\",\n\t \"datePublished\": \"2024-07-19T13:30:00+00:00\",\n\t \"dateModified\": \"2024-07-29T20:33:16+00:00\",\n\t \"mainEntityOfPage\": {\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\\\/\"\n\t },\n\t \"wordCount\": 406,\n\t \"commentCount\": 0,\n\t \"publisher\": {\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\"\n\t },\n\t \"keywords\": [\n\t \"Eli Lilly\",\n\t \"future trends\",\n\t \"stock market\"\n\t ],\n\t \"articleSection\": [\n\t \"North America\",\n\t \"Region\",\n\t \"Securities\",\n\t \"Stocks\",\n\t \"Text Articles\",\n\t \"Traders' Insight\"\n\t ],\n\t \"inLanguage\": \"en-US\",\n\t \"potentialAction\": [\n\t {\n\t \"@type\": \"CommentAction\",\n\t \"name\": \"Comment\",\n\t \"target\": [\n\t \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\\\/#respond\"\n\t ]\n\t }\n\t ]\n\t },\n\t {\n\t \"@type\": \"WebPage\",\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\\\/\",\n\t \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\\\/\",\n\t \"name\": \"Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain | IBKR Campus US\",\n\t \"isPartOf\": {\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#website\"\n\t },\n\t \"datePublished\": \"2024-07-19T13:30:00+00:00\",\n\t \"dateModified\": \"2024-07-29T20:33:16+00:00\",\n\t \"description\": \"Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.\",\n\t \"inLanguage\": \"en-US\",\n\t \"potentialAction\": [\n\t {\n\t \"@type\": \"ReadAction\",\n\t \"target\": [\n\t \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\\\/\"\n\t ]\n\t }\n\t ]\n\t },\n\t {\n\t \"@type\": \"WebSite\",\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#website\",\n\t \"url\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/\",\n\t \"name\": \"IBKR Campus US\",\n\t \"description\": \"Financial Education from Interactive Brokers\",\n\t \"publisher\": {\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\"\n\t },\n\t \"potentialAction\": [\n\t {\n\t \"@type\": \"SearchAction\",\n\t \"target\": {\n\t \"@type\": \"EntryPoint\",\n\t \"urlTemplate\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/?s={search_term_string}\"\n\t },\n\t \"query-input\": {\n\t \"@type\": \"PropertyValueSpecification\",\n\t \"valueRequired\": true,\n\t \"valueName\": \"search_term_string\"\n\t }\n\t }\n\t ],\n\t \"inLanguage\": \"en-US\"\n\t },\n\t {\n\t \"@type\": \"Organization\",\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\",\n\t \"name\": \"Interactive Brokers\",\n\t \"alternateName\": \"IBKR\",\n\t \"url\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/\",\n\t \"logo\": {\n\t \"@type\": \"ImageObject\",\n\t \"inLanguage\": \"en-US\",\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/logo\\\/image\\\/\",\n\t \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2024\\\/05\\\/ibkr-campus-logo.jpg\",\n\t \"contentUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2024\\\/05\\\/ibkr-campus-logo.jpg\",\n\t \"width\": 669,\n\t \"height\": 669,\n\t \"caption\": \"Interactive Brokers\"\n\t },\n\t \"image\": {\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/logo\\\/image\\\/\"\n\t },\n\t \"publishingPrinciples\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/about-ibkr-campus\\\/\",\n\t \"ethicsPolicy\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/cyber-security-notice\\\/\"\n\t },\n\t {\n\t \"@type\": \"Person\",\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/person\\\/8aec5ebeb263dcb77586039ad857f7ae\",\n\t \"name\": \"Tim Fries\",\n\t \"description\": \"Tim Fries is a managing director at Lakeview Capital, adviser to the founders and head of U.S. business development. He has a B.Sc. in Mechanical Engineering from the University of Michigan and an MBA from the University of Chicago Booth School of Business. Tim is also the co-founder of Protective Technologies Capital (protechcap.com) and Lakeview Capital, as well as the co-founder of the financial education site The Tokenist. Prior to founding Protective Technologies, Tim was a member of Baird Capital's global Industrial Solutions private equity team. He writes on topics related to wealth management, private capital market investing and trends in the convergence of finance and technology (i.e. FinTech).\",\n\t \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/author\\\/tim-fries\\\/\"\n\t }\n\t ]\n\t}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain","description":"Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interactivebrokers.com\/campus\/wp-json\/wp\/v2\/posts\/209349\/","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain | IBKR Campus US","og_description":"Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.","og_url":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/","og_site_name":"IBKR Campus US","article_published_time":"2024-07-19T13:30:00+00:00","article_modified_time":"2024-07-29T20:33:16+00:00","author":"Tim Fries","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tim Fries","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/#article","isPartOf":{"@id":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/"},"author":{"name":"Tim Fries","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/person\/8aec5ebeb263dcb77586039ad857f7ae"},"headline":"Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain","datePublished":"2024-07-19T13:30:00+00:00","dateModified":"2024-07-29T20:33:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/"},"wordCount":406,"commentCount":0,"publisher":{"@id":"https:\/\/ibkrcampus.com\/campus\/#organization"},"keywords":["Eli Lilly","future trends","stock market"],"articleSection":["North America","Region","Securities","Stocks","Text Articles","Traders' Insight"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/","url":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/","name":"Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain | IBKR Campus US","isPartOf":{"@id":"https:\/\/ibkrcampus.com\/campus\/#website"},"datePublished":"2024-07-19T13:30:00+00:00","dateModified":"2024-07-29T20:33:16+00:00","description":"Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/stocks\/eli-lilly-enters-the-chinese-market-as-tirzepatide-gains-approval-shares-gain\/"]}]},{"@type":"WebSite","@id":"https:\/\/ibkrcampus.com\/campus\/#website","url":"https:\/\/ibkrcampus.com\/campus\/","name":"IBKR Campus US","description":"Financial Education from Interactive Brokers","publisher":{"@id":"https:\/\/ibkrcampus.com\/campus\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibkrcampus.com\/campus\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ibkrcampus.com\/campus\/#organization","name":"Interactive Brokers","alternateName":"IBKR","url":"https:\/\/ibkrcampus.com\/campus\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/logo\/image\/","url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2024\/05\/ibkr-campus-logo.jpg","contentUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2024\/05\/ibkr-campus-logo.jpg","width":669,"height":669,"caption":"Interactive Brokers"},"image":{"@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/logo\/image\/"},"publishingPrinciples":"https:\/\/www.interactivebrokers.com\/campus\/about-ibkr-campus\/","ethicsPolicy":"https:\/\/www.interactivebrokers.com\/campus\/cyber-security-notice\/"},{"@type":"Person","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/person\/8aec5ebeb263dcb77586039ad857f7ae","name":"Tim Fries","description":"Tim Fries is a managing director at Lakeview Capital, adviser to the founders and head of U.S. business development. He has a B.Sc. in Mechanical Engineering from the University of Michigan and an MBA from the University of Chicago Booth School of Business. Tim is also the co-founder of Protective Technologies Capital (protechcap.com) and Lakeview Capital, as well as the co-founder of the financial education site The Tokenist. Prior to founding Protective Technologies, Tim was a member of Baird Capital's global Industrial Solutions private equity team. He writes on topics related to wealth management, private capital market investing and trends in the convergence of finance and technology (i.e. FinTech).","url":"https:\/\/www.interactivebrokers.com\/campus\/author\/tim-fries\/"}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts\/209349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/users\/501"}],"replies":[{"embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/comments?post=209349"}],"version-history":[{"count":0,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts\/209349\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/media?parent=209349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/categories?post=209349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/tags?post=209349"},{"taxonomy":"contributors-categories","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/contributors-categories?post=209349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}